SYRS vs KYMR vs ARVN vs IMVT vs TNGX

For growth investors, Tango Therapeutics, Inc.

(TNGX) is the stronger pick with 48. 3% revenue growth year-over-year, versus -33. 2% for Syros Pharmaceuticals, Inc. (SYRS). Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tango Therapeutics, Inc.

(TNGX) delivered a total return of +117. 2%, compared to -100. 0% for Syros Pharmaceuticals, Inc. (SYRS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SYRS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arvinas, Inc.

(ARVN) is the lower-risk stock at 1. 15β versus Tango Therapeutics, Inc. 's 1. 81β — meaning TNGX is approximately 58% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for Syros Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Tango Therapeutics, Inc.

(TNGX) is pulling ahead at 48. 3% versus -33. 2% for Syros Pharmaceuticals, Inc. (SYRS). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, TNGX leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -1656. 3% for Syros Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -1298. 2% for SYRS. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Tango Therapeutics, Inc. (TNGX) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +154. 4%, TNGX: +129. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SYRS is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; ARVN is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; TNGX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.